Skip to content
Back to search results

AIMS: Abnormal Involuntary Movement Scale

Introduced by
National Institute of Mental Health
Year
1976
Type
Clinician-rated observation
Family
Tardive dyskinesia and antipsychotic medication side effects
Font size

What does it do?

The Abnormal Involuntary Movement Scale (AIMS) is the standard clinical rating scale for assessing tardive dyskinesia, a iatrogenic movement disorder resulting from chronic antipsychotic medication exposure.

Developed by the National Institute of Mental Health in 1976, the 12-item scale systematically measures involuntary movements across facial, oral, limb, and trunk regions. The AIMS is mandatory screening tool for patients on long-term antipsychotic therapy and essential for monitoring antipsychotic-associated movement complications.

The intuition behind the method

Antipsychotic medications, particularly older first-generation agents (haloperidol, fluphenazine) and high-potency agents, block dopamine D2 receptors in basal ganglia causing motor side effects. Early effects (hours to days) include acute dystonia and akathisia; with chronic exposure (weeks to months), parkinsonism develops; with years of treatment, tardive dyskinesia emerges in 20-30% of patients—involuntary choreiform, athetoid, or dystonic movements of face, lips, tongue, and limbs. Tardive dyskinesia is difficult to treat and often persists even after medication discontinuation. The AIMS provides systematic, reproducible quantification of these abnormal movements enabling baseline documentation, progression monitoring, and medication adjustment decisions. Early detection allows intervention (dose reduction, medication switch) potentially preventing dyskinesia establishment.

History

Tardive dyskinesia was recognized as antipsychotic medication side effect in the 1960s (Schoenecker 1957, Faurbye et al. 1964). Initial descriptive accounts called for objective measurement tools. The National Institute of Mental Health developed the AIMS in 1976, published in a comprehensive NIMH manual, as standardized assessment for research and clinical monitoring of involuntary movements. The AIMS became mandatory for NIH-funded clinical trials and FDA-monitored antipsychotic safety assessments. DSM-IV and DSM-5 use AIMS criteria as part of tardive dyskinesia diagnostic definition. Modern atypical antipsychotics (olanzapine, risperidone, aripiprazole) have lower tardive dyskinesia risk than typical agents, but cumulative incidence remains 2-3% per year in older adults. AIMS remains gold-standard despite introduction of alternative measures (Dyskinesia Identification System Condensed User Scale, DISCUS).

When to use it

Baseline AIMS assessment recommended before initiating antipsychotic medication (within 1 week). Repeated AIMS every 6-12 months during antipsychotic treatment (FDA and American Psychiatric Association recommend ≥annually). Mandatory if patient reports involuntary movements or after antipsychotic dose increase (dyskinesia more common at higher cumulative doses). Essential before any long-term antipsychotic use in patients >40 years old or with tardive dyskinesia risk factors (older age, female sex, mood disorder, African American ethnicity). Serial AIMS guides medication adjustments: improvement suggests dose reduction/discontinuation feasibility; worsening suggests continued dose optimization or alternative agent consideration.

Limitations and considerations

  • Subjective rating of movement severity (mild vs moderate) subject to inter-rater variability despite training; videotape standardization helps but does not eliminate variability.
  • Does not quantify movement frequency objectively; some raters may emphasize slow-frequency large-amplitude movements (more visible) while others detect rapid small-amplitude tremor. Standardization training critical.
  • Dental status item (item 12) conflates with dyskinesia severity and may not be independent; some versions exclude this item.
  • Baseline movement detection limited if patient intentionally suppresses movements or is unaware of mild dyskinesia; repeat assessments with explicit instruction to avoid voluntary suppression improve reliability.
  • Does not differentiate etiology of movements (tardive dyskinesia vs Parkinson's tremor vs essential tremor vs cerebellar ataxia); clinical history and other neurological signs required.
  • Most sensitive in orofacial region; limb dyskinesia may be underdetected if examiner does not observe during specific movement tasks (arm extension, finger tapping).

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Gold-standard assessment tool for tardive dyskinesia; 50+ years of clinical validation and use globally.
  • Simple binary observation-based rating (no patient cooperation required beyond performing movements); does not rely on subjective complaint or patient insight.
  • Excellent inter-rater reliability (ICC 0.85-0.95) when raters trained via videotape standardization.
  • Sensitive to dyskinesia presence and severity; discriminates absence from mild/moderate/severe dyskinesia effectively.
  • Practical for routine clinical care; 10-15 minute administration fits into standard clinic visit.
  • Enables early detection of dyskinesia before functional impairment develops, permitting preventive medication adjustments.

Applications

  • Antipsychotic medication safety monitoring: baseline AIMS (pre-medication) compared with serial AIMS (annually) tracks tardive dyskinesia incidence and progression; documents medication-related adverse event for medical-legal purposes.
  • Clinical decision-making regarding medication adjustments: AIMS score guides antipsychotic selection (atypical preferred if possible), dose optimization (consider reduction if AIMS increasing), and discontinuation decisions (weigh benefit vs dyskinesia risk).
  • Research phenotyping of tardive dyskinesia: AIMS scores enable subtyping (orofacial-predominant vs generalized dyskinesia) and investigation of genetic and environmental risk factors (age, sex, ethnicity, cumulative dose, duration of exposure).
  • Regulatory safety monitoring: FDA Post-Marketing Surveillance uses AIMS data in spontaneous report analysis of antipsychotic safety; AIMS-documented tardive dyskinesia cases inform medication labeling and risk communication.
  • Clinical trial outcomes: tardive dyskinesia trials use AIMS as primary endpoint (e.g., testing valbenazine or tetrabenazine efficacy in treating established dyskinesia); treatment-induced AIMS change measures drug efficacy.
  • Patient advocacy and informed consent: AIMS provides quantitative documentation of tardive dyskinesia severity enabling patient counseling regarding realistic movement expectations and treatment benefits/risks.

How it works

How it works

1

Structured clinical observation in quiet, comfortable setting. Patient seated for 1 minute at rest; examiner observes facial, oral, and limb movements. Then examiner instructs: (1) 'Extend arms in front of you, palms down' (observe 10 seconds for hand/finger dyskinesia); (2) 'Open mouth, stick out tongue as far as you can' (observe 10 seconds for oral-lingual movements); (3) 'Tap the back of your fingers on the chair, like this' (demonstrates and observes patient's rapidly alternating finger tapping for tremor/dyskinesia). Examiner also assesses: gait and posture (standing and walking), presence of global tremor, and patient awareness of abnormal movements. Complete examination requires 10-15 minutes. Ideally performed with patient off medications for 24 hours (most sensitive for dyskinesia detection), though not required clinically.

Formula
Clinician observes patient during standardized examination assessing involuntary movements. Patient seated comfortably, observed at rest for 1 minute. Then patient instructed through series of movements: extend arms and hands forward (observe hand/finger tremor, dyskinesia); open mouth and protrude tongue (observe oral-lingual movements); tap fingers on chair rapidly (observe fingers/hands). Observation period approximately 10 minutes total including rest periods and movement tasks.
2

12 items rated 0-4 (none/minimal/mild/moderate/severe). (1-4) Upper extremity involuntary movements, lower extremity, lips, jaw (facial region movements). (5-7) Tongue, lingual region, oral dyskinesia overall. (8) Neck, shoulders, hips/trunk movements. (9) Global severity rating (0-4) of all involuntary movements. (10) Patient awareness of dyskinesia (0-4: none/minimal/aware of movements/aware and concerned/severe distress). (11) Incapacity related to dyskinesia (0-4: none to severe). (12) Dental status (0 = natural teeth, 1 = dentures, 2 = no teeth). Total AIMS score = sum of items 1-11 = 0-44 (some use 0-40 excluding dental item). Scoring done after observation; clinician uses judgment for ratings based on observed movement frequency and amplitude.

Formula
12 items rated on 5-point scale (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe) assessing involuntary movements in: facial region, lips, jaw, tongue, upper extremities, lower extremities, neck/trunk (7 items); plus oral dyskinesia severity, global severity overall, and patient's awareness of dyskinesia (3 items); plus dental status (1 item). Total AIMS score 0-40. Higher scores indicate greater dyskinesia severity.

Common pitfalls

  • Comparing AIMS scores across different raters without standardization training; untrained raters may systematically over- or under-score dyskinesia severity. Ensure all raters complete video-based AIMS training module.
  • Administering AIMS while patient actively taking anti-parkinsonian medications (benztropine, trihexyphenidyl) that suppress dyskinesia; medication should be withheld 24 hours prior for valid assessment (though not practical in all settings). Document medication status at time of AIMS.
  • Missing orofacial movements by failing to observe during mouth-opening task; tongue dyskinesia (protrusion, involuntary movements) commonly present. Ensure patient fully protrudes tongue and examiner observes 10+ seconds.
  • Attributing all involuntary movements to tardive dyskinesia without considering alternative diagnoses (medication-induced akathisia causing restlessness rather than orofacial dyskinesia; essential tremor causing hand tremor; tics). AIMS alone does not establish etiology.
  • Failing to obtain baseline AIMS before antipsychotic initiation, making dyskinesia incidence assessment impossible. Establish baseline in all patients starting antipsychotic, even if movement detection unlikely.
  • Interpreting stable AIMS score as absence of tardive dyskinesia risk; many patients show gradual AIMS increase over years. Serial assessments with trend analysis more informative than single score.

Frequently asked questions

What is the difference between tardive dyskinesia and akathisia?

Tardive dyskinesia is involuntary choreiform or dystonic movement (observable orofacial/limb dyskinesia) developing after chronic antipsychotic exposure. Akathisia is subjective feeling of inner restlessness and inability to sit still, with or without visible movement. AIMS measures dyskinesia (observable movements); akathisia requires separate assessment (patient subjective report or Akathisia Rating Scale). Patients may have both simultaneously. Akathisia may respond to beta-blockers; dyskinesia typically does not.

Can tardive dyskinesia improve or resolve?

Early tardive dyskinesia (<2 years onset) may partially resolve with dose reduction or antipsychotic discontinuation (30-50% improvement). Established tardive dyskinesia (>2 years) often persists despite medication changes but may improve slowly over years. Recent FDA-approved medications (valbenazine, tetrabenazine) treat established dyskinesia; approximately 40-50% patients achieve ≥25% AIMS reduction with these agents. Younger patients and shorter dyskinesia duration at treatment initiation predict better treatment response.

How often should AIMS be repeated?

FDA and professional guidelines recommend baseline AIMS (before/within 1 week of antipsychotic initiation) and repeat every 6-12 months during treatment. Higher-risk patients (age >40, prior dyskinesia, African American, female) warrant more frequent assessment (every 3-6 months). Immediately repeat if patient develops subjective awareness of involuntary movements or if antipsychotic dose increased. More frequent assessment (monthly) appropriate in clinical dyskinesia treatment trials.

What AIMS score constitutes 'tardive dyskinesia'?

There is no single cutoff score. Diagnostic criteria require: (a) current AIMS score >4 (≥2 items scored ≥2, OR ≥1 item scored ≥3) on any region. PLUS (b) ≥3 months antipsychotic exposure OR ≥1 month exposure and recent dose change. PLUS (c) dyskinesia not attributable to other medical conditions (hyperthyroidism, hypoglycemia, stroke). Baseline AIMS at pre-treatment establishes baseline; subsequent increase suggests antipsychotic-induced dyskinesia. Some patients score >4 at baseline (idiopathic movements); careful baseline assessment is essential.

Does AIMS assess other movement disorders?

AIMS specifically measures involuntary dyskinetic movements (orofacial and limb dyskinesia). It does NOT measure parkinsonism (bradykinesia, rigidity, resting tremor)—assessed separately via Extrapyramidal Symptom Rating Scale (ESRS) or Unified Parkinson's Disease Rating Scale (UPDRS). It does NOT measure akathisia (subjective restlessness)—assessed via subjective report or Akathisia Rating Scale. AIMS purely measures observable involuntary choreiform/athetoid movements.

Related methods

Sources

  1. National Institute of Mental Health (1976). Abnormal Involuntary Movement Scale (AIMS). In: Rockland, L. H., Schooler, N. R., & Levine, J. (Eds.), Drug Treatment of Mental Disorders. New York: Raven Press.

    Open publication reference
    Copied.